Table 1. Meta-analysis of the association between the ERCC5 Asp1104His polymorphism and cancer risk under the XP recessive genetic model for 49 studies.

Variables	No. of studies	No. of subjects Cases/controls	His/His vs. Asp/Asp			His/His vs. Asp/His+Asp/Asp
			OR (95%CI)c	P OR a	P het b	OR (95%CI)c	P OR a	P het b
All	49	23490/27168	0.99 (0.92–1.06)	0.707	0.242	0.98 (0.93–1.03)	0.393	0.260
Cancer type
Breast	9	4915/5277	0.99 (0.85–1.15)	0.882	0.362	0.95 (0.83–1.09)	0.497	0.420
Skin	8	3909/4263	0.95 (0.78–1.16)	0.622	0.586	0.98 (0.86–1.13)	0.809	0.782
Lung	5	4702/5654	0.99 (0.86–1.15)	0.937	0.032	0.98 (0.90–1.06)	0.566	0.049
Bladder	5	2304/2253	0.94 (0.74–1.20)	0.621	0.112	0.95 (0.75–1.21)	0.686	0.083
Head and neck	3	1429/1954	0.90 (0.67–1.22)	0.510	0.194	0.88 (0.67–1.16)	0.364	0.240
Colorectal	3	743/879	0.97 (0.59–1.58)	0.900	0.372	0.92 (0.57–1.48)	0.720	0.262
NHL	3	2105/1957	1.07 (0.83–1.38)	0.594	0.238	1.03 (0.80–1.32)	0.839	0.345
Others	13	3383/4931	1.02 (0.86–1.21)	0.850	0.384	1.03 (0.89–1.19)	0.696	0.244
Ethnicity
Caucasian	29	13316/15586	0.99 (0.89–1.10)	0.814	0.287	0.98 (0.90–1.08)	0.709	0.452
African-American	4	1318/1330	1.11 (0.89–1.38)	0.365	0.020	1.03 (0.86–1.24)	0.747	0.016
Asian	6	2314/2443	0.90 (0.76–1.06)	0.216	0.292	0.93 (0.82–1.06)	0.262	0.091
Others	10	6542/7809	1.00 (0.88–1.15)	0.982	0.878	0.98 (0.90–1.07)	0.679	0.852
Source of controls
Hospital	27	9787/11586	0.95 (0.85–1.05)	0.298	0.186	0.97 (0.89–1.05)	0.426	0.129
Population	20	10333/11150	1.02 (0.91–1.14)	0.732	0.325	0.99 (0.89–1.09)	0.795	0.427
Others	2	3370/4432	1.02 (0.85–1.23)	0.810	0.853	0.98 (0.90–1.08)	0.706	0.795
Sample size
<500	33	7469/10388	0.98 (0.87–1.11)	0.755	0.055	0.96 (0.86–1.06)	0.396	0.067
500–1000	11	8170/7890	1.02 (0.90–1.15)	0.781	0.704	1.01 (0.91–1.11)	0.923	0.649
>1000	5	7851/8890	0.96 (0.84–1.09)	0.516	0.893	0.97 (0.90–1.05)	0.474	0.916

^a P value of the Z-test for odds ration test.

^b P value of the Q-test for heterogeneity test.

^cFixed effects model.